Vascular Hysteresis Loops and Vascular Architecture Mapping in Patients with Glioblastoma treated with Antiangiogenic Therapy

Andreas Stadlbauer1,2, Max Zimmermann1, Stefan Oberndorfer3, Arnd Doerfler4, Michael Buchfelder1, Gertraud Heinz2 & Karl Roessler1

In this study, we investigated the variability of vascular hysteresis loop (VHL) shapes and the spatial heterogeneity of neovascularization and microvascular alterations using vascular architecture mapping (VAM) in patients with recurrent glioblastoma during bevacizumab mono-therapy. VAM data were acquired in 13 patients suffering from recurrent glioblastoma prior to and 3 months after bevacizumab treatment onset using a dual contrast agent injections approach as part of routine MRI. Two patients were additionally examined after the first cycle of bevacizumab to check for early treatment response. VHLs were evaluated as biomarker maps of neovascularization activity: microvessel type indicator (MTI) and curvature (Curv) of the VHL-long-axis. Early response to bevacizumab was dominated by reduction of smaller microvasculature (around 10 µm). In the 3-month follow-up, responding tumors additionally showed a reduction in larger microvasculature (>20 µm). VAM biomarker images revealed spatially heterogeneous microvascular alterations during bevacizumab treatment. Responding, non-responding, progressive, and remote-progressive tumor areas were observed. MTI may be useful to predict responding and non-responding tumor regions, and Curv to assess severity of vasogenic edema. Analysis of VHLs in combination with VAM biomarkers may lead to a new perspective on investigating the spatial heterogeneity of neovascularization and microvascular alterations in glioblastoma during antiangiogenic therapy.

Glioblastoma (GB) is the most aggressive primary brain tumor in adults with an elevated expression of vascular endothelial growth factor (VEGF) protein, which has been identified as a critical regulator of tumor angiogenesis, endothelial cell proliferation, and migration1. Thereby, GBs are among the most vascularized of all solid tumors showing a disorganized, abundant and aberrant vasculature with tortuous vessels of variable diameter, heterogeneous distribution2, and abnormal capillary bed topology3. GBs are therefore attractive targets for antiangiogenic therapies (AAT)4 and the VEGF-specific antibody bevacizumab was approved by the Food and Drug Administration (FDA) for this purpose in 20095. Administration of bevacizumab in humans has been shown that magnetic resonance imaging (MRI) based tumor volume criteria doesn’t make sense for response assessment in GBs6 even though its criteria have been updated by the Response Assessment in Neuro-Oncology (RANO) working group7. The major challenge is the decreased vessel permeability8, which results in diminished contrast agent extravasation9 but does not necessarily reflect biological tumor response10.

Computer simulations as well as experiments in animals and humans have demonstrated that more advanced MRI techniques can estimate microvascular vessel caliber, thereby providing further insight into tissue microvascularity11-14. The physical basis for MRI-based vessel caliber estimation is the different sensitivity of gradient-echo (GE) and spin-echo (SE) MRI to magnetic susceptibility11-13. The highly susceptibility-sensitive GE signals are dominated by a broad range of larger microvessel diameters (starting from 20 µm, i.e. larger arterioles and venules)15, with reduced sensitivity to the smaller microvascular range15. In contrast, despite its lower overall sensitivity to contrast agent-induced signal variations, SE signals exhibits a peak sensitivity to the microvasculature

1Department of Neurosurgery, University of Erlangen-Nürnberg, Erlangen, Germany. 2Institute of Medical Radiology, University Clinic of St. Pölten, St. Pölten, Austria. 3Department of Neurology, University Clinic of St. Pölten, St. Pölten, Austria. 4Department of Neuroradiology, University of Erlangen-Nürnberg, Erlangen, Germany. Correspondence and requests for materials should be addressed to A.S. (email: andi@nmr.at)
at a vessel diameter around 10 µm\(^{11}\), including capillaries and both small arterioles and venules. These differences in sensitivity to the vascular properties were shown in simulations studies\(^{11,14}\) and verified in practice\(^{16}\).

Kiselev et al.\(^{15}\) were the first who reported about a “loop” in the parametric plot of the relaxation rates for GE (\(\Delta R_{2,GE}^{2/3}\)) versus SE (\(\Delta R_{2,SE}^{3/2}\)) first-pass peaks in dynamic susceptibility contrast (DSC) perfusion MRI. They found that the shape of the loop and the direction of its passage may differ between normal brain and tumor tissue. Xu et al.\(^{17}\) demonstrated by considering a tree model of microvasculature, that the direction of the loop is influenced mainly by the relative arterial and venous blood volume, as well as by the tracer bolus dispersion. These findings were confirmed by Hsu et al.\(^{18}\) by using a dual contrast agent injections approach. Emblem et al.\(^{19}\) recently detected an additional vasculature-dependent effect on the MR signals: a temporal shift between GE and SE signals, which influences the formation of the loop curve too. Depending on the hemodynamic properties of a tissue, the different sensitivities of the GE and SE signals to larger and smaller microscopic vessels resulted in a temporal shift between the respective MRI signal readouts. They demonstrated that patients with recurrent GBs, who responded to AAT with reduced tumor vessel calibers and improved hemodynamic efficiency survived longer than patients without these responses. This promising technique, however, has yet not found its way into clinical routine diagnostics. Reasons for this could be the lack of both clinically compatible MRI sequence protocols and imaging biomarkers considering the temporal shift phenomenon. Furthermore, a detailed analysis of the diversity of loop curve shapes in patients with glioblastoma and their changes during antiangiogenic therapy have not been presented so far.

In this study we used a MRI sequence protocol which is compatible to and practicable for clinical routine diagnostics in order to investigate the diversity and the changes of vascular hysteresis loop (VHL) shapes in patients suffering from recurrent GBs during bevacizumab mono-therapy. VHL analysis was extended with MRI biomarkers adapted to the temporal shift phenomenon. This approach, termed vascular architecture mapping (VAM), was used for investigating the spatial heterogeneity of neovascularization activity and microvascular changes due to bevacizumab treatment.

**Results**

Calculation of VHLs and the VAM approach are illustrated in Fig. 1. Interpretation of VHLs was performed in accordance with the findings of Emblem et al.\(^{19}\) and Xu et al.\(^{17}\). In areas with faster blood flow velocities, i.e. in voxels with arteriole dominated microvasculature (red squares in Fig. 1a), the GE-EPI perfusion signal peaked earlier than the SE-EPI perfusion signal (left diagram in the red-framed part of Fig. 1b) and the VHL traversed in clockwise direction (right diagram in the red-framed part of Fig. 1b). Whereas, the SE-EPI perfusion signal peaked earlier than the GE-EPI perfusion signal (left diagram in the blue-framed part of Fig. 1b) and the VHL traversed in the counterclockwise direction (right diagram in the blue-framed part of Fig. 1b) if the vascular system in a voxel was dominated by venule- and capillary-like vessel components with slower blood flow velocities (blue squares in Fig. 1a). For purposes of comparison, VHLs for voxel positions with arteriole dominated microvasculature (Fig. 1b, top right) and venule/capillary dominated microvasculature (Fig. 1b, bottom right) in edema (gray VHL), contralateral normal white matter (cNWM, light green), and contralateral normal gray matter (cNGM, dark green) are depicted in relation to the tumor VHL.

Accordingly to our definition for the calculation of microvessel type indicator (MTI) values, a counterclockwise VHL-direction was associated with a negative signed VHL-area, i.e. a negative MTI, and vice-versa for the clockwise VHL direction. In MTI maps, negative values were assigned to cool colors and positive to warm colors, respectively. Consequently, maps of MTI enabled discrimination between supplying arterial (areas with warm colors in the topmost image in Fig. 1c) and draining venous microvasculature (areas with cool colors in the topmost image in Fig. 1c). Maps of microvessel density (\(N_c\), second image in Fig. 1c) and microvessel radius (\(R_c\), third image in Fig. 1c) showed heterogeneous patterns of mildly to severely increased levels. Areas with severely increased \(N_c\) showed a rather mild increase in \(R_c\) and vice versa, i.e. maps of \(N_c\) and \(R_c\) provided complementary information about the heterogeneity of the microvasculature in GB. The Curv parameter showed almost exclusively negative values. Curv values in the tumor core were similar compared to ipsi- and contralateral normal appearing brain (NAB). Curv was severely decreased, i.e. showed severely larger negative values, in peritumoral vasogenic edema when compared to ipsi- and contralateral NAB.

During bevacizumab treatment, VHLs and VAM biomarker images revealed massive but spatially heterogeneous changes in microvascular architecture. We observed (i) tumor areas with decreased neovascularization activity interpreted as response to AAT; (ii) tumor areas with unchanged and increased neovascularization activity interpreted as non-response to AAT; and (iii) areas with newly developed neovascularization activity interpreted as progression during AAT.

A representative case of a patient suffering from recurrent GB who showed both response and non-response image parameters to bevacizumab treatment is illustrated in Fig. 2. Compared to the baseline examination response was associated with a distinct reduction in the VHL-area in the follow-up examination. This was observed for both venule/capillary (blue-framed VHLs in Fig. 2b) and arteriole dominated (magenta-framed VHLs in Fig. 2b) microvasculature. Both parameters of the VHL, \(\Delta R_{2,GE}^{2/3}\) and \(\Delta R_{2,SE}^{3/2}\), were reduced in the follow-up examination. Interpreting these data means, tumor vasculature was reduced in both larger and smaller microvasculature. The VHLs in non-responding tumor areas showed an increase in area due to both an increase in \(\Delta R_{2,GE}^{2/3}\) (i.e. larger microvasculature) and \(\Delta R_{2,SE}^{3/2}\) (i.e. smaller microvasculature; see cyan-framed VHLs in Fig. 2b). Response to antiangiogenic therapy in the posterior tumor part was accompanied with a distinct reduction in peritumoral edema (Fig. 2a) which was associated with an increase in VHL-area (black-framed VHLs in Fig. 2b). As can be seen from the VHLs (black-framed VHLs in Fig. 2b), these vascular changes in peritumoral edema were dominated by an increase in microvascular perfusion (i.e. increase in \(\Delta R_{2,GE}^{2/3}\)). Note: the voxel positions for the VHLs are marked with squares in the CE T1w and FLAIR images in Fig. 2a, which have the same
color as the frames of the VHLs. The MTI and \( N_U \) images clearly revealed a spatial segregation in responding and non-responding tumor areas. The posterior tumor parts showed an increase in MTI (i.e. less negative MTI values) and decrease in \( N_U \) as indication for decreased neovascularization activity as response to anti-angiogenic treatment. The anterior part of the tumor, however, showed an unaltered high or even increasing neovascularization activity: highly negative or decreasing MTI values, and high or increasing \( N_U \) values, respectively. The changes in the \( R_U \) images were less distinct. Reduction in peritumoral edema was accompanied with a massive increase in the Curv parameter (less negative Curv values; see image at the bottom of Fig. 2c).

Figure 3 illustrates a patient suffering from a recurrent GB who obtained an additional MR examination including the VAM experiments for early AAT response detection after the first dose of bevacizumab, i.e. after 2 weeks. The second follow-up examination was performed after 3 months of AAT onset, as with all the other patients. In this patient, responding tumor vasculature showed very similar changes between the baseline and the 3-month follow-up examination compared with those in Fig. 2 (compare blue-framed VHLs in Figs 2b and 3b): \( \Delta R_{2,GE} \) and \( \Delta R_{2,SE}^{1/2} \) were reduced in the 3-month follow-up examination. Interestingly, the VHL at the early follow-up after 2 weeks showed only a reduction in \( R_{2,SE}^{1/2} \), i.e. a therapeutic effect in the small microvasculature of the tumor (blue-framed VHLs in Fig. 3b). Non-responding tumor vasculature showed also similar changes between the baseline and the 3-month follow-up examination compared with those in Fig. 2 (compare magenta-framed VHLs in Figs 2b and 3b): \( \Delta R_{2,GE} \) and \( \Delta R_{2,SE}^{1/2} \) were increased in the 3-month follow-up examination. In the 2-week follow-up, however, no change occurred in the VHL compared to baseline (magenta-framed VHLs in Fig. 3b). In this patient we additionally detect an area with partial response after the first dose bevacizumab (2-week follow-up) characterized with a strong reduction in \( \Delta R_{2,GE} \) but not in \( \Delta R_{2,SE}^{1/2} \), followed by a
relapse at the 3-month follow-up characterized by an increase in both $\Delta R_{2,GE}$ and especially in $\Delta R_{2,SE}^{3/2}$ (cyan-framed VHLs in Fig. 3b). Again, the MTI and $N_U$ images clearly revealed a spatial segregation in responding, non-responding, partial responding and relapsing tumor areas. Although the tumor showed areas with non-response, the MTI images showed progression, FLAIR images showed a reduction in peritumoral edema accompanied by ‘normalization’ of the VHL at the selected voxel position. The Curv image, however, revealed dynamic changes in the whole peritumoral area (image at the bottom of Fig. 3c).

A patient with response, progression, and remote progression in the contralateral hemisphere during AAT is depicted in Fig. 4. Again, the changes in the VHLs for the responding tumor vasculature were similar compared to the other patients (compare blue-framed VHLs in Figs 2b, 3b and 4b). This patient, however, showed progression of the GB almost into the entire vicinity. A representative VHL in this area showed an increase in both $\Delta R_{2,GE}$ and $\Delta R_{2,SE}^{3/2}$ due to the tumor progression (magenta-framed VHLs in Fig. 4b). A small area in the remote...
progression in the contralateral hemisphere showed even a change from an arterial-dominated to a venule/capillary-dominated vasculature (cyan-framed VHLs in Fig. 4b). These distinct changes in neovascularization activity were clearly detected and visualized in the MTI and NU maps, respectively. Additionally, the posterior part of the edema showed no regression but partly even a progression on the Curv map (image at the bottom of Fig. 4c), which is accompanied with a further reduction in both $\Delta R_{2,SE}^{3/2}$ and VHL-area (black-framed VHLs in Fig. 4b).

All 13 patients included in this study showed areas with response to bevacizumab, nine patients additionally showed non-response, and eight patients additionally showed a progression of the GB during AAT. The changes for the MTI, NU, and RU in these three different tumor areas for each patient individually are depicted in Fig. 5a–c. The changes of the Curv parameter in peritumoral edema in the vicinity of responding, non-responding, and progressive tumor parts are depicted in Fig. 5d. Mean values ($\pm$sd) for the four VAM biomarkers in the three different tumor areas and the associated peritumoral edematous areas are summarized in Table 1. MTI, NU, and RU were significant different between the 3-month follow-up compared to base-line: responding tumor areas showed an increase in MTI and a decrease in NU and RU; non-responding tumor areas and progression, however, showed a decrease in MTI and an increase in NU and RU. As realized from investigation of the individual cases, Curv was most sensitive to changes in peritumoral edema.

Comparison of VAM biomarker values at baseline examination between tumor regions which showed response and non-response at the 3-month follow-up in order to check for potential predicting factors revealed significant ($P = 0.042$) higher MTI values at baseline in tumor areas which responded in the follow-up $(MTI(baseline)_{response} = -82.2 \pm 60.4)$ compared to the tumor area which not responded in the follow-up $(MTI(baseline)_{non-response} = -147.8 \pm 80.2)$. All the other VAM biomarkers showed no significant differences at baseline.

Figure 3. Vascular hysteresis loops and VAM biomarker maps for a 54-year-old male patient suffering from a recurrent glioblastoma before AAT onset (baseline, bl), at early 2-week follow-up (“fu 2wk”), and at 3-month follow-up (“fu 3mo”). (a) Conventional MRI (cMRI) included contrast-enhanced T1-weighted (CE T1w), FLAIR, GE-EPI DSC perfusion evaluated as maps of cerebral blood flow (CBV), and DWI evaluated as apparent diffusion coefficient (ADC), respectively. (b) VHLs, i.e. the $\Delta R_{2,GE}$ (y-axis) versus $\Delta R_{2,SE}^{3/2}$ (x-axis) diagrams, for a voxel position in the responding (blue-framed VHLs), non-responding (magenta), partial responding tumor with relapse (cyan), and for edema in the vicinity of the non-responding tumor (black). The voxel positions are marked with squares in the CE T1w and FLAIR images in (a) and have the same color as the frames of the VHLs. The arrows indicate the rotational direction of the VHLs. (c) The maps of the microvessel type indicator (MTI), the upper limit for microvessel density (NU) and radius (RU) adapted to the temporal shift phenomenon, and the curvature (Curv) of the VHL (top-down). The color codes are depicted at the right image margins.
Analysis of VHLs in combination with the VAM approach demonstrated three features for investigation of the microvasculature of GBs:

i) estimation of the microvascular compartments (ratio of larger vs. smaller microvessel);

ii) estimation of the microvascular type (arterioles vs. capillaries vs. venules); and

iii) estimation of the spatial heterogeneity of neovascularization activity and its changes during AAT by evaluating features i and ii via calculation of VAM biomarker images.

Firstly, investigation of the two VHL-variables, especially of the maxima of $\Delta R_{2,GE}$ and $\Delta R_{2,SE}^{3/2}$, allowing for a vessel-caliber-dependent estimation of the microvascular compartments within a voxel. A voxel dominated by larger microvessels showed relatively higher max[$\Delta R_{2,GE}$] and vice-versa for a voxel dominated by smaller microvessels with higher max[$\Delta R_{2,SE}^{3/2}$]. This feature enabled us to differentiate the effects of bevacizumab on larger and smaller microvasculature: early 2-week follow-up showed a reduction in max[$\Delta R_{2,SE}^{3/2}$] (i.e. smaller microvasculature) in responding tumor regions, but no or minor changes in max[$\Delta R_{2,GE}$]. In the 3-month follow-up, however, the max[$\Delta R_{2,GE}$] increased in these regions, indicating an up-regulation of larger microvessels as a response to bevacizumab. The results are summarized in Table 1.
follow-up, however, responding tumor regions showed a reduction in max $[\Delta R_{2,GE}]$ (larger microvasculature) too. To the best of our knowledge this differentiation of effects of bevacizumab on the larger and smaller microvasculature at early and delayed follow-up was not described so far. Emblem et al. recently built on the hysteresis effect, which was originally described by Kiselev et al. more than a decade ago, and demonstrated that AAT of recurrent GBs using cediranib can improve microcirculation and reduce vessel calibers. This response was associated with prolonged patient survival. An analysis of the dynamic changes of the VHLs, however, was not performed in this study.

Secondly, analysis of the VHL-direction enables the estimation of the microvascular type which dominates a voxel: faster-inflow (arterioles-dominated) vs. slow-inflow (venules-dominated) assessed by rotational direction of the VHL (clockwise vs. counterclockwise). This was previously described with computer simulations under consideration of a tree model of microvasculature and was expanded by the temporal shift phenomenon between max $[\Delta R_{2,SE}]$ and max $[\Delta R_{2,GE}]$. A detailed interpretation of the temporal shift, however, was not presented so far. Considering both the maxima and the direction of the VHL may be helpful to explain the temporal shift phenomenon. In a voxel dominated by larger (faster-flow) arterioles and capillaries the blood with the

Figure 5. Changes for the (a) MTI, (b) $N_{uv}$ and (c) $R_{uv}$ for each patient individually in responding (all 13 patients), non-responding (9 patients) tumor, and in tumor progression (8 patients). (d) Shows the changes of the Curv parameter in peritumoral edema associated with the tumor areas in (a–c): edema in the vicinity of responding tumor, non-responding tumor, and tumor progression, respectively. Note: bl = baseline; fu = 3-month follow-up.
capillary compartment. This is in accordance with results from computer simulations. It is well-known that is associated with more than two reversal points. In other words, the VHL segment of reversal represents the ous studies from Kiselev ous studies published used a double-dose for the combined GE-SE perfusion and/or applied a second be a reason for the limited application in clinical routine of this promising technique. Additionally, most previ- quantification, however, is critically dependent on a high temporal resolution. This is also true for a longer TE. The accuracy of the hysteresis of the SE-EPI perfusion sequence are a further limitations. Applying a larger acquisition matrix would increase two separate SE- and GE-DSC acquisitions is significantly more sensitive to both patient motions and variations in injection timing compared to a combined GE-SE sequence. Our strategies help to minimize the probability of these sources of error but cannot eliminate them entirely. Moreover, the injection of a double dose of contrast agent in combination with a separate injections is required. On the other hand, our approach with separate SE- and GE-DSC injection for perfusion MRI and correction of leakage effects is the efforts to upgrade the combined GE-SE in injection timing compared to a combined GE-SE sequence. Our strategies helped to minimize the probability of these sources of error but cannot eliminate them entirely. Moreover, the injection of a double dose of contrast agent with two separate injections is required. On the other hand, our approach with separate SE- and GE-DSC sequences allowing the acquisition of VAM data with high SNR, high spatial resolution, and coverage of the whole brain, which is mandatory for routine GE-EPI perfusion. The combined GE-SE sequence used in previous studies tended rather to show response to AAT in the follow-up than regions with higher neovascularization activity. This might be an indication for the known vascular niche which is thought of as protective microenvironment that enables glioblastoma stem cells to freely proliferate and remain undifferentiated, completely unaffected by any external influences. The Curv parameter might be a marker for the severity of vasogenic edema and compression of small microvessels due to increased interstitial pressure in the edema. However, there is no verified histopathologic basis for an interrelationship so far. Correlations with DTI data, histologic parameters, and Monte Carlo simulations for VHL formation could be informative.

This study has several limitations. First of all, the dual contrast agent injections approach in combination with two separate SE- and GE-DSC acquisitions is significantly more sensitive to both patient motions and variations in injection timing compared to a combined GE-SE sequence. Our strategies help to minimize the probability of these sources of error but cannot eliminate them entirely. Moreover, the injection of a double dose of contrast agent with two separate injections is required. On the other hand, our approach with separate SE- and GE-DSC sequences allowing the acquisition of VAM data with high SNR, high spatial resolution, and coverage of the whole brain, which is mandatory for routine GE-EPI perfusion. The combined GE-SE sequence used in previous studies, however, does not meet these requirements and may necessitate performing the routine GE perfusion in addition or in a separate study, which consequently requires a further contrast agent injection. This might be a reason for the limited application in clinical routine of this promising technique. Additionally, most previous studies published used a double-dose for the combined GE-SE perfusion, and/or applied a second injection for perfusion MRI or correction of leakage effects. The efforts to upgrade the combined GE-SE perfusion sequence with the promising Simultaneous-MultiSlice (SMS) technique for full coverage may help to overcome these limitations. The interpolation to the target resolution, which potentially influences the magnitude of the measured susceptibility effect, and the short TE, which reduces contrast agent sensitivity and hence SNR, of the SE-EPI perfusion sequence are further limitations. Applying a larger acquisition matrix would increase TR and consequently the temporal resolution. This is also true for a longer TE. The accuracy of the hysteresis quantification, however, is critically dependent on a high temporal resolution.

| MTI | Ex. | Tumor response | Tumor non-resp. | Tumor progress | Edema response | Edema non-resp. | Edema progress | cNAB |
|-----|-----|----------------|----------------|---------------|---------------|---------------|---------------|------|
|     |     | (N = 13)*      | (N = 9)*       | (N = 8)*      | (N = 13)*     | (N = 9)*      | (N = 8)*      |      |
| [R]2 | fu  | −82.2 ± 60.4   | −147.8 ± 80.2  | −6.0 ± 5.8    | 0.3 ± 1.0     | −0.4 ± 1.1    | −0.5 ± 1.2    | 0.0 ± 0.7 |
| [μm] | fu  | −4.2 ± 6.4*    | −196.0 ± 78.7* | −67.1 ± 66.1* | −1.4 ± 2.7    | −0.1 ± 2.6    | 0.4 ± 2.9     | 0.2 ± 0.6 |
| Curv | bl  | 498 ± 132      | 277 ± 125      | 101 ± 52      | 120 ± 43      | 151 ± 53      | 180 ± 37      |
|     | fu  | 212 ± 103*     | 511 ± 170*     | 173 ± 94*     | 162 ± 43*     | 129 ± 48      | 164 ± 28      |
|     | bl  | 102 ± 45       | 42 ± 19        | 83 ± 44       | 61 ± 18       | 43 ± 19       | 29 ± 7        |
| Curv | bl  | 6.0 ± 36*      | 84 ± 53*       | 54 ± 27       | 77 ± 33       | 91 ± 28*      | 28 ± 6        |
|     | fu  | −7.6 ± 11      | −22 ± 22       | −197 ± 97     | −140 ± 55     | −33 ± 24      | −15 ± 6       |
|     | bl  | −85 ± 103*     | −30 ± 79       | −11 ± 13      | −49 ± 7*      | −118 ± 82     | −179 ± 76*    |

Table 1. VAM biomarker values in three different tumor areas and peritumoral edema. Values are mean values ± standard deviation. *In parentheses: number of patients. **Values marked with an asterisks are significant (P < 0.05) different to the value at the baseline examination. Note: MTI = microvessel type indicator; Nv = microvessel density; Re = microvessel radius; Curv = curvature of the long-axis of the VHL; Exam. = examination; bl = baseline; fu = 3-month follow-up, cNAB = contralateral normal appearing brain.
In summary, analysis of VHLs in combination with VAM biomarkers is capable of both, assessing the topological and structural heterogeneity of tumor microcirculation, and monitoring the response to and the progression during bevacizumab treatment. This approach may lead to a new perspective on investigating microvascular changes in glioma and other brain pathologies as well as on therapy monitoring. However, validations of the biomarkers are required to enable rational interpretation.

Methods

Patients. This study was approved by the Institutional Review Boards of the University of Erlangen and the University Clinic of St. Pölten. Analysis of patient data and all methods were performed in accordance with both the Declaration of Helsinki and the relevant guidelines and regulations. Written informed consent for both study participation and publication of information/images was obtained from all subjects. Between July 2015 and December 2016, fifteen patients (7 women, 8 men; 55.6 ± 13.3 years) suffering from recurrent glioblastoma who received bevacizumab (Avastin®; Roche; every 2 weeks 10 mg/kg-bodyweight) as second-line mono-therapy were included in this study. From the 15 patients, 2 patients (13%) with severe neurological deficits were excluded due to patient motion between or during the MR scans.

MR Imaging. All MRI studies were performed on a 3 Tesla clinical MR scanner (Tim Trio; Siemens, Erlangen, Germany) equipped with a standard 12-channel head coil. MR examinations were performed 1–5 days prior to (baseline) and 3 months after bevacizumab treatment onset (follow-up). In two patients a MRI examination was additionally performed after the first cycle of bevacizumab (two weeks after onset) in order to check for early response to treatment.

The clinical routine MRI protocol included an axial fluid-attenuated inversion-recovery (FLAIR) sequence (TR/TE/TI: 5000/460/1800 ms; in-plane resolution: 0.45 × 0.45 mm; slice thickness: 3 mm; 48 slices; 2 averages; acquisition time, TA: 3.85 min), a single-shot diffusion-weighted echo-planar imaging (DW-EPI) sequence (TR/TE: 5300/98 ms; in-plane resolution: 1.2 × 1.2 mm, slice thickness: 4 mm; 29 slices; 4 averages; parallel imaging using generalized autocalibrating partially parallel acquisition (GRAPPA) factor of 2, b-values of 0 and 1000 s/mm²; TA: 1.3 min), and pre- and post-contrast enhanced (CE) T1-weighted GE sequences (TR/TE: 250/2.8 ms; in-plane resolution: 0.5 × 0.5 mm, slice thickness: 4 mm; 29 slices; 2 averages).

For VAM we used a dual contrast agent injections approach in order to obtain DSC perfusion MRI data using SE- and GE-EPI sequences with high signal-to-noise ratio (SNR), high spatial resolution, and coverage of the whole brain. However, patient motions between the two scans as well as differences in the time to first-pass peak may significantly affect the data evaluation. To minimize the probability of these sources of error we used the following strategies as described previously:

i) To prevent patient motion, special caution was made to properly fix the head and provide clear and repeated patient instructions before and during the MRI examination. Due to the fact that patient motions during or between the SE- and GE-EPI DSC perfusion scans may significantly affect a pixel-based analysis, we used the approach described by Hsu et al. to detect patient motion: During data preprocessing, dynamic masks for the contours from the SE- and GE-EPI perfusion raw data were created. By matching the contours, we checked for patient motion between and during the scans. A mismatch of more than one pixel was defined as ‘severe patient motion’, which was an exclusion criterion of this study from further evaluation. This was necessary in two patients as mentioned above. For the remaining 13 patients we did not observe significant motions, i.e. contour mismatch was not more than one pixel, and thus no image coregistration was applied during data analysis.

ii) To prevent time differences of the first-pass peak signal between the contrast agent boluses a peripheral pulse unit (PPU) was fitted to a finger of the patients in order to monitor heart rate and cardiac cycle. Special attention was paid to perform the two injections at the same heart rate and exactly at the same phase of the cardiac cycle (at PPU’s peak systole signal). Due to the fact that timing differences between the SE- and GE-EPI DSC perfusion scans may significantly affect a pixel-based analysis, we additionally checked for any error in injection timing. During data preprocessing the arterial input functions (AIFs) for the SE- and GE-EPI DSC perfusion data were verified for correct timing, i.e. we checked for differences in the time to peak (TTP) between the two AIFs. For all 28 examinations included in this study we did not observe differences between the SE- and GE-AIFs of the respective examination.

Geometric parameters (section orientation, angulation, field-of-view, etc.) and measurement parameters were chosen identical for the SE- and GE-EPI DSC sequences: TR, 1740 ms; in-plane resolution, 1.8 × 1.8 mm; SE-EPI were spatially interpolated to a 128 × 128 matrix; slice thickness, 4 mm; 29 slices; GRAPPA, 2; 60 dynamic measurements; and TA: 2.0 min, respectively. TE was different between SE- (33 ms) and GE-EPI (22 ms). Both DSC perfusion MRI examinations were performed with administration of 0.1 mmol/kg-bodyweight gadoterate meglumine (Dotarem, Guerbet) at a rate of 4 ml/s using a MR-compatible injector (Spectris, Medrad) and with utmost caution for the injection time (see above). A 20 ml bolus of saline was injected subsequently at the same rate. The first DSC MRI was obtained by the SE-EPI technique since SE-EPI DSC perfusion MRI is less sensitive to contrast-agent leakage. CE T1-weighted images in axial, sagittal, and coronal orientation were performed between two DSC perfusion acquisitions. The total acquisition time of the three CE T1w sequences was 8 minutes. Thereafter the second DSC MRI was obtained using the GE-EPI technique during a bolus injection under the same conditions as for the SE-EPI DSC acquisition.

MRI data processing. VAM analysis was performed using custom-made in-house software developed using MATLAB (MathWorks, Natick, MA, USA). SE- and GE-EPI DSC data were imported into the software and checked for motion artifacts during or between the acquisitions. Next, AIFs for the SE- and GE-EPI DSC data were automatically identified in each slice using automatic segmentation of brain tissue sub-classes in DSC concentration-time curves. In short, concentration-time curves were assumed to belong to one of five tissue sub-classes (white matter, gray matter, arterial blood, venous blood, or ‘other’), and multiple features (first
moment of the concentration–time curves integral, peak height, time to peak height, and bolus arrival time) were used to assign each concentration–time curves into the most probable tissue class. The average of five concentration–time curves with the lowest first moment and the highest average peak height was then selected as the final AIF\(^{31}\). \(\Delta R(t)\)\(_{2,SE}\) and \(\Delta R(t)\)\(_{2,GE}\) were calculated from the signals of the SE- and GE-EPI DSC data using the following equation:

\[
\Delta R(t)_{2,XE} = -\frac{1}{TE_{XE}} \cdot \ln \left( \frac{S(t)_{XE}}{S_0,XE} \right)
\]

(1)

where XE stands for SE or GE, respectively. TE is the echo time, S\(_0\) is the baseline (prebolus) signal, and S(t) is the signal during the first bolus passage of the corresponding sequence. S\(_0\) was determined as the mean of the signals from the 4th to the 15th dynamic volume\(^{38}\). For S(t), the respective DSC perfusion MR data were corrected for remaining contrast agent extravasation\(^{32,33}\) and a minimum search between the first and the second bolus passage (caused by recirculation) was performed as described previously\(^{37}\) in order to separate the boluses. The truncated \(\Delta R(t)\)\(_{2,SE}\) and \(\Delta R(t)\)\(_{2,GE}\) curves of the first bolus were fitted to a previously described gamma-variate function\(^{14}\) and used for calculation of the \(\Delta R_{2,GE}\) versus \(\Delta R_{2,SE}\) diagram (Fig. 1b), which we termed vascular hysteresis loop (VHL).

**MR imaging biomarkers of microvascular architecture.** The VHL of each voxel was evaluated by the following four parameters: i) microvessel type indicator (MTI) as the signed area of the VHL; ii) microvessel density \(N_U\) and iii) radius \(R_U\) which were adapted of the temporal shift phenomenon; and iv) the curvature \(\text{Curv}\) of the long-axis of the VHL (Fig. 1c). We termed this approach vascular architecture mapping (VAM).

In a first step, the MTI parameter was defined as the area of the VHL signed with the rotational direction of the VHL, i.e. clockwise VHL-direction was identified with a plus-sign and counterclockwise VHL-direction was identified with a minus-sign. MTI values were calculated by subtraction of the areas under the ascending branch of the VHL minus the descending branch of the VHL (we refer to the VHLs for tumor in Fig. 1b). The maximum \(\Delta R_{2,SE}\) value was defined as reversal point.

In the second step, the temporal shift phenomenon between the SE- and GE-EPI DSC signal time courses was considered by calculation of the maximum Q-index

\[Q_{\text{max}} = \frac{\max(\Delta R_{2,GE})}{\max(\Delta R_{2,SE})}\]

(2)

for each VHL. This is equivalent to the calculation of the slope of the diagonal of the enveloping rectangle of the VHL. \(Q_{\text{max}}\) takes into account that the maxima of the \(\Delta R_{2,GE}\) and \(\Delta R_{2,SE}\) values, i.e. \(\max(\Delta R_{2,GE})\) and \(\max(\Delta R_{2,SE})\), are separated in the VHL when a vascular-architecture-induced temporal shift between the dynamic SE- and GE-perfusion MRI signals exists (see VHLs for tumor in Fig. 1b).

Thirdly, \(N_U\) and \(R_U\), which previously introduced by Jensen \text{et al.}\(^{35}\), were adapted to the temporal shift phenomenon by using the following equations

\[N_U = \frac{Q_{\text{max}}}{b} \left( \frac{\text{CBV}^2}{4\pi^2 \cdot \text{ADC} \cdot R} \right)^{1/3}\]

(3)

and

\[R_U = \left( \frac{\text{CBV} \cdot \text{ADC} \cdot b}{2\pi \cdot Q_{\text{max}}} \right)^{1/2}\]

(4)

where ADC is the apparent diffusion coefficient which was calculated from the DW-EPI MRI data. CBV is the cerebral blood volume which was calculated from the GE-EPI DSC perfusion MRI data. R is the mean vessel lumen radius \(R \approx 3.0 \mu m\) and b is a numerical constant \((b = 1.6781)\) as described previously\(^{39}\), which has nothing to do with diffusion weighting.

Finally, the Curv parameter was introduced to assess the shape of the VHL deviating from a symmetric ellipse which is associated with differences in the width of the GE- and SE-EPI perfusion boluses. The Curv values were calculated by fitting of the long-axis of the VHL with a quadratic polynomial followed by determination of the second derivative.

**Statistics.** Software (SPSS 14, IBM, Chicago, IL, USA) was used for statistical evaluation. The mean values for the four VAM biomarkers within seven regions of interest (ROI) were calculated. These ROIs were manually defined by an experienced neuroradiologist (A.D.) based on features seen in FLAIR images, CE T1w MRIs, and VAM images, respectively. ROIs were located in: i) tumor regions responding to bevacizumab with decreased neovascularization; ii) non-responding tumor regions with unchanged or increased neovascularization; iii) areas with newly developed neovascularization activity interpreted as progression during AAT; edema in the vicinity of iv) responding; v) non-responding; and vii) progressive tumor viii) as well as contralateral normal appearing brain tissue (cNAB) of predominantly white matter. Differences in VAM biomarkers between baseline and 3-month follow-up examination were determined using a Wilcoxon signed-rank test. In order to check for potential predicting factors, we compared VAM biomarker values at baseline examination between tumor regions which showed response and non-response at the 3-month follow-up, respectively, using a Mann-Whitney U test. P values of less than 0.05 were considered to indicate significance.
References

1. Vidiri, A. et al. Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation. J Exp Clin Cancer Res 31, 33 (2012).

2. Dvorak, H. F. How Tumors Make Bad Blood Vessels and Stroma. Am. J. Pathol. 162, 1747–1757 (2016).

3. Pries, A. R., Hopfen, M., le Noble, F., Dewhirst, M. W. & Sescob, T. W. The shunt problem: control of functional shunting in normal and tumour vasculature. Nat Rev Cancer 10, 587–593 (2010).

4. Reuten, O. et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA 108, 3749–3754 (2011).

5. Kreis, T. N. et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27, 740–745 (2009).

6. Macdonald, D. R., Cascino, T. L., Schold, S. C. & Cairncross, J. G. Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8, 1277–1280 (1990).

7. Wen, P. Y. et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28, 1963–1972 (2010).

8. Hicklin, D. J. & Ellis, L. M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23, 1011–1027 (2005).

9. Pope, W. B., Lai, A., Nghiemphu, P., Mischel, P. & Cloughesy, T. F. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66, 1258–1260 (2006).

10. Verhoeff, J. J. et al. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 9, 444 (2009).

11. Boxerman, J. L., Hamborg, I. M., Rosen, B. R. & Weisskoff, R. M. MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med 34, 555–566 (1995).

12. Dennie, J. et al. NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med 40, 793–799 (1998).

13. Kiselev, V. G., Streck, R., Zvyev, S., Speck, O. & Hennig, J. Vessel size imaging in humans. Magn Reson Med 53, 553–563 (2005).

14. Weisskoff, R. M., Zuo, C. S., Boxerman, J. L. & Rosen, B. R. Microscopic susceptibility variation and transverse relaxation: theory and experiment. Magn Reson Med 31, 601–610 (1994).

15. Schmiedeskamp, H. et al. Combined spin- and gradient-echo perfusion-weighted imaging. Magn. Reson. Med. 68, 30–40 (2012).

16. Speck, O., Chang, L., Menaka DeSilva, N. & Ernst, T. Perfusion MRI of the human brain with dynamic susceptibility contrast: Gradient-echo versus spin-echo techniques. J. Magn. Reson. Imaging 12, 381–387 (2000).

17. Xu, C., Kiselev, V. G., Möller, H. E. & Fiebach, J. B. Dynamic hysteresis between gradient echo and spin echo attenuations in dynamic susceptibility contrast imaging. Magn. Reson. Med. 69, 981–991 (2013).

18. Hsu, Y.-Y., Wang, W.-S., Lim, K.-E. & Liu, H.-L. Vessel size imaging using dual contrast agent injections. J. Magn. Reson. Imaging 30, 1078–84 (2009).

19. Emblem, K. E. et al. Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med 19, 1178–1183 (2013).

20. Stadlbauer, A. et al. Recurrence of glioblastoma is associated with elevated microvascular transit time heterogeneity and increased hypoxia. J. Cereb. Blood Flow Metab. in-press (2017).

21. Calabrese, C. et al. A Perivascular niche for brain Tumor Stem Cells. Cancer Cell 11, 69–82 (2007).

22. Gilbertson, R. J. & Rich, J. N. Making a tumour’s bed: glioblastoma stem cells and the vascular niche. Nat. Rev. Cancer 7, 733–736 (2007).

23. Batchelor, T. T. et al. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc. Natl Acad. Sci. 110, 19059–19064 (2013).

24. Schmianida, K. M. et al. Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis. Am. J. Neuroradiol. 25, 1524–1532 (2004).

25. Sorensen, A. G. et al. ‘A vascular normalization index’ as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 69, 5296–5300 (2009).

26. Eichner, C. et al. Slice accelerated gradient-echo spin-echo dynamic susceptibility contrast imaging with blipped CAIPI for increased slice coverage. Magnetic Resonance in Medicine 72, 779–778 (2013).

27. Griswold, M. A. et al. Generalized Autocalibrating Partially Parallel Acquisitions (GRAPPA). Magn. Reson. Med. 47, 1202–1210 (2002).

28. Stadlbauer, A. et al. Magnetic resonance imaging biomarkers for clinical routine assessment of microvascular architecture in glioma. J. Cereb. Blood Flow Metab. 37, 632–643 (2017).

29. Carroll, T. J. et al. Quantification of cerebral perfusion using the ‘bookend technique’: an evaluation in CNS tumors. Magn. Reson. Imaging 26, 1352–1359 (2008).

30. Essig, M. et al. Dynamic susceptibility contrast-enhanced echo-planar imaging of cerebral gliomas. Effect of contrast medium extravasation. Radiol. 43, 354–359 (2002).

31. Bjornrud, A. & Emblem, K. E. A fully automated method for quantitative cerebral hemodynamic analysis using DSC-MRI. J Cereb Blood Flow Metab 30, 1066–1078 (2010).

32. Boxerman, J. L. et al. The role of preload and leakage correction in gadolinium-based cerebral blood volume estimation determined by comparison with MION as a criterion standard. Am. J. Neuroradiol. 33, 1081–1087 (2012).

33. Boxerman, J. L., Schmianida, K. M. & Weisskoff, R. M. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. Am. J. Neuroradiol. 27, 859–867 (2006).

34. Ducorre, D. et al. Perfusion-weighted MR imaging studies in brain hypervascular diseases: comparison of arterial input function extractions for perfusion measurement. AJNR Am J Neuroradiol 27, 1059–1069 (2006).

35. Jensen, J. H., Lu, H. & Inglese, M. Microvessel density estimation in the human brain by means of dynamic contrast-enhanced echo-planar imaging. Magn. Reson. Med. 56, 1145–1150 (2006).

Acknowledgements

This work was supported by the German Research Foundation (Deutsche Forschungsgemeinschaft – DFG; Grant Numbers STA 1331/3-1 and DO 721/8-1) and by the ELAN program (Erlander Leistungsbezogene Anschubfinanzierung und Nachwuchsförderung; Grant Number 14-05-21-1-Stadlbauer).

Author Contributions

A.S., A.D., M.B. and K.R. conceived the study. A.S. and M.Z. involved in analysis of data. A.S. and M.Z. contributed to the development of the MRI biomarkers of microvascular architecture. A.S., G.H., A.D. and K.R. involved interpretation of data. A.S., G.H., and S.O. contributed to acquisition of data. All authors reviewed the manuscript critically for intellectual content, and read and approved the final manuscript.
Additional Information

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017